Administration of miltefosine and meglumine antimoniate In healthy dogs: Clinicopathological evaluation of the impact on the kidneys

Toxicologic Pathology

Volumn 37, Issue 6, 2009, Pages 770-775

  Bianciardi, Paolo ^a   Brovida, Claudio ^b   Valente, Marialuisa ^c   Aresu, Luca ^d   Cavicchioli, Laura ^d   Vischer, Claudia ^e   Giroud, Lucie ^e   Castagnaro, Massimo ^d  

^a ANUBI Ospedale per Animali da Compagnia ^*

^b Anubi Ospedale per Animali da Compagnia   (Italy)

^c UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

^d Virbac SA   (France)

^e DVM Milano   (Italy)

Author keywords

Dogs; Kidney; Leishmania; Meglumine antimoniate; Miltefosine; Pharmacological effect

Indexed keywords

MEGLUMINE ANTIMONATE; MILTEFORAN; MILTEFOSINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROL GROUP; CONTROLLED STUDY; DOG; ELECTRON MICROSCOPY; FEMALE; FOLLOW UP; IMMUNOFLUORESCENCE; KIDNEY BIOPSY; KIDNEY TUBULE DAMAGE; KIDNEY TUBULE NECROSIS; LEISHMANIASIS; MALE; MICROSCOPY; NONHUMAN; PATHOLOGY; PRIORITY JOURNAL; TREATMENT DURATION; ULTRASOUND;

ANIMALS; ANTIPROTOZOAL AGENTS; BODY WEIGHT; DOGS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HISTOCYTOCHEMISTRY; KIDNEY; KIDNEY DISEASES; KIDNEY TUBULES; LEISHMANIASIS; MALE; MEGLUMINE; MICROSCOPY, ELECTRON; ORGANOMETALLIC COMPOUNDS; PHOSPHORYLCHOLINE; RANDOM ALLOCATION; TOXICITY TESTS;

ANIMALIA; CANIS FAMILIARIS;

EID: 70649115295     PISSN: 01926233     EISSN: 15331601     Source Type: Journal    
DOI: 10.1177/0192623309344088     Document Type: Article

References (33)

1. Aresu, L., Pregel, P., Bollo, E., Palmerini, D., Sereno, A., and Valenza, F. (2008) Immunofluorescence staining for the detection of immunoglobulins and complement (C3) in dogs with renal disease. Vet Rec 163, 679-82.
2. Aresu, L., Rastaldi, M. P., Pregel, P., Valenza, F., Radaelli, E., Scanziani, E., and Castagnaro, M. (2008) Dog as model for down-expression of E-cadherin and beta-catenin in tubular epithelial cells in renal fibrosis. Virchows Arch 453, 617-25.
3. Baneth, G. (2006). Leishmaniases. In Infectious diseases of the dog and cat (3rd ed.), ed. C. E. Green, 685-98. Philadelphia: Saunders.
4. Baneth, G., Koutinas, A. F., Solano-Gallego, L., Bourdeau, P., and Ferrer, L. (2008). Canine leishmaniosis-new concepts and insights on an expanding zoonosis: part one. Trends Parasitol 24, 324-30.
5. Baneth, G., and Shaw, S. E. (2002). Chemotherapy of canine leishmaniosis. Vet Parasitol 106, 315-24.
6. Belloli, C., Ceci, L., Carli, S., Tassi, P., Montesissa, C., De Natale, G., Marcotrigiano, G., and Ormas, P. (1995). Disposition of antimony and aminosidine in dogs after administration separately and together: implications for therapy of leishmaniasis. Res Vet Sci 58, 123-27.
7. Berman, J. (2005) Miltefosine to treat leishmaniasis, Expert Opin Pharmacother 6, 1381-88.
8. Bravo, L., Frank, L. A., and Brenneman, K. A. (1993). Canine leishmaniasis in the United States. Compendium on Continuing Education for the Practicing Veterinarian 15, 699-708.
9. Ciaramella, P., Oliva, G., Luna, R. D., Gradoni, L., Ambrosio, R., Cortese, L., Scalone, A., and Persechino, A. (1997). A retrospective clinical study of canine leishmaniosis in 150 dogs naturally infected by Leishmania infantum. Vet Rec 141, 539-43.
10. Costa, F. A., Goto, H., Saldanha, L. C., Silva, S. M., Sinhorini, I. L., Silva, T. C., Guerra, J. L. (2003). Histopathologic patterns of nephropathy in naturally acquired canine visceral leishmaniasis. Vet Pathol 40, 677-84.
11. Davidson, R. N. (1998). Practical guide for treatment of leishmaniasis. Drugs. 56, 1009-18.
12. Hantson, P., Luyasu, S., Haufroid, V., and Lambert, M. (2000). Antimony excretion in a patient with renal impairment during meglumine antimoniate therapy. Pharmacotherapy 20, 1141-43.
13. Hilgard, P., Klenner, T., Stekar, J., and Unger, C. (1993). Alkylphosphocholines: a new class of membrane active anticancer agents. Cancer Chemother Pharmacol 32, 90-95.
14. Ikeda-Garcia, F. A., Lopes, R. S., Ciarlini, P. C., Marques, F. J., Lima, V. M., Perri, S. H., and Feitosa, M. M. (2007). Evaluation of renal and hepatic functions in dogs naturally infected by visceral leishmaniasis submitted to treatment with meglumine antimoniate. Res Vet Sci 83, 105-8.
15. Jha, T. K., Sunder, S., Thakur, C. P., Bachmann, P., Karbwang, J., Fischer, C., Voss, A., and Berman, J. (1999). Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N Engl J Med 341, 1795-1800.
16. Koutinas, A. F., Polizopoulou, Z. S., Saridomichelakis, M. N., Argyriadis, D., Fytianou, A., and Plevraki, K. G. (1999). Clinical considerations on canine visceral leishmaniasis in Greece: A retrospective study of 158 cases (1989-1996). J Am Anim Hosp Assoc 35, 376-83.
17. Mateo, M., Maynard, L., Vischer, C., Bianciardi, P., and Miró, G. (2009) Comparative study on the short term efficacy and adverse effects of miltefosine and meglumine antimoniate in dogs with natural leishmaniosis. Parasitol Res 105, 155-62.
18. Miró, G., Oliva, G., Cruz, I., Canavate, C., Mortarino, M., Vischer, C., and Bianciardi, P. (2008). Multi-centric and controlled clinical field study to evaluate the efficacy and safety of the combination of miltefosine and allopurinol in the treatment of canine leishmaniosis. Vet Dermatol 19 (Suppl 1), 7-8.
19. Miró, G., Cardoso, L., Pennisi, M. G., Oliva, G., and Baneth, G. (2008). Canine leishmaniosis-new concepts and insights on an expanding zoonosis: Part two. Trends Parasitol 24, 371-77.
20. Nieto, C. G., Navarrete, I., Habela, M. A., Serrano, F., and Redondo, E. (1992). Pathological changes in kidneys of dogs with natural Leishmania infection. Vet Parasitol 45, 33-47.
21. Noli, C. (1999). Leishmaniosis canina. Waltham Focus 9, 16-24.
22. Noli, C., and Auxilia, S. T. (2005). Treatment of canine Old World visceral leishmaniasis: A systematic review. Vet Dermatol 16, 213-32.
23. Pearson, R. D. (2003). Development status of miltefosine as first oral drug in visceral and cutaneous leishmaniasis. Curr Infect Dis Rep. 5, 41-42.
24. Rodrigues, M. L., Costa, R. S., Souza, C. S., Foss, N. T., and Roselino, A. M. (1999). Nephrotoxicity attributed to meglumine antimoniate (Glucantime) in the treatment of generalized cutaneous leishmaniasis. Rev Inst Med Trop Sao Paulo 41, 33-37.
25. Sundar, S., Gupta, L. B., Makharia, M. K., Singh, M. K., Voss, A., Resenkaimer, F., Engel, J., Murray, H. W. (1999). Oral treatment of visceral leishmaniasis with miltefosine. Ann Trop Med Parasitol 93, 589-97.
26. Sundar, S., Rosenkaimer, F., Makharia, M. K., Goyel, A. K., Mandal, A. K., Voss, A., Hilgard, P., and Murray, H. W. (1998). Trial of oral miltefosine for visceral leishmaniasis. Lancet 352, 1821-23.
27. Tassi, P., Ormas, P., Madonna, M., Carli, S., Belloli, C., De Natale, G., Ceci, L., and Marcotrigiano, G. O. (1994). Pharmacokinetics of N-methylglucamine antimoniate after intravenous, intramuscular and subcutaneous administration in the dog. Res Vet Sci 56, 144-50.
28. Verma, N. K., and Dey, C. S. (2004) Possible Mechanism of Miltefosine-Mediated Death of Leishmania donovani. Antimicrob Agents Chemother 48, 3010-15.
29. Veiga, J. P., Khanam, R., Rosa, T. T., Junqueira Júnior, L. F., Brant, P. C., Raick, A. N., Friedman, H., and Marsden, P. D. (1990). Pentavalent antimonial nephrotoxicity in the rat. Rev Inst Med Trop Sao Paulo 32, 304-9.
30. Virbac Data On File, European Registration Dossier: Study No. F-107.010000-60008.
31. Virbac Data On File, European Registration Dossier: Study No. F-107.000000-40010.
32. Virbac Data On File, European Registration Dossier: Study No. F-107.000000-40027 [Toutain, P. L., (2006) Expert Report: Study of the pharmacokinetics of miltefosine in plasma, urine and faeces of dogs after oral repeated administrations of miltefosine in food for 28 days: Pharmacokinetic Analysis Report].
33. Zatelli, A., Borgarelli, M., Santilli, R., Bonfanti, U., Nigrisoli, E., Zanatta, R., Tarducci, A., and Guarraci, A. (2003). Glomerular lesions in dogs infected with Leishmania organisms. Am J Vet Res 64, 558-61.